PMID- 21320029
OWN - NLM
STAT- MEDLINE
DCOM- 20110720
LR  - 20161018
IS  - 1437-4331 (Electronic)
IS  - 1434-6621 (Linking)
VI  - 49
IP  - 5
DP  - 2011 May
TI  - Quantification of HER2 autoantibodies in the amplification phenomenon of HER2 in 
      breast cancer.
PG  - 877-83
LID - 10.1515/CCLM.2011.135 [doi]
AB  - BACKGROUND: Gene amplification of HER2 (human epidermal growth factor receptor 2) 
      is a well-known phenomenon in various cancers. However, little is known about the 
      mechanism of the gene amplification phenomenon itself. Autoantibodies to cellular 
      receptors have been described in several cancer types. We hypothesised that 
      autoantibodies against HER2 might have a stimulatory capacity and could be the 
      cause of the HER2 gene amplification phenomenon. To investigate this, we 
      developed a test for the detection of autoantibodies against HER2 in serum 
      (S-HER2Ab). METHODS: Blood and tissue samples were collected from 311 women 
      consecutively admitted for surgical treatment of primary breast cancer. Paraffin 
      embedded tissue sections were analysed by immunohistochemistry (IHC) and 
      fluorescence in situ hybridization (FISH). HER2 protein concentrations in tissue 
      were determined in 115 patients. Circulating extracellular domain of HER2 
      (S-HER2) was measured using the Advia Centaur (Siemens AG, Munich, Germany). 
      Analysis for autoantibodies was developed on an ImmunoCAP 100 (Phadia AB, 
      Uppsala, Sweden) with an automated Fluorescent Enzyme Immuno Assay. RESULTS: Of 
      311 women, 55 (17.7%) had HER2Ab and 51 (16.4%) showed amplification of the HER2 
      gene determined by IHC/FISH. Eleven women had detectable S-HER2Ab as well as HER2 
      gene amplification, but no statistically significant correlation was found 
      between the two phenomena. A significantly higher level of S-HER2Ab was found 
      both in HER2 gene-amplified and non-amplified breast cancer patients compared to 
      an age-matched healthy control group. No statistically significant difference in 
      presence or concentration of S-HER2Ab was found in HER2 gene-amplified vs. 
      non-amplified breast cancer. CONCLUSIONS: S-HER2Ab can be measured accurately 
      with the ImmunoCAP 100. There is an increased prevalence and concentration of 
      S-HER2Ab in breast cancer patients but no correlation with HER2 gene 
      amplification. We conclude that autoantibodies against HER2 do not seem to be the 
      cause of HER2 gene amplification.
FAU - Lauterlein, Jens-Jacob L
AU  - Lauterlein JJ
AD  - Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark. 
      jejala@dadlnet.dk
FAU - Petersen, Eva R B
AU  - Petersen ER
FAU - Olsen, Dorte Aa
AU  - Olsen DA
FAU - Ostergaard, Birthe
AU  - Ostergaard B
FAU - Brandslund, Ivan
AU  - Brandslund I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110215
PL  - Germany
TA  - Clin Chem Lab Med
JT  - Clinical chemistry and laboratory medicine
JID - 9806306
RN  - 0 (Autoantibodies)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Autoantibodies/*blood/immunology
MH  - Blood Chemical Analysis/*methods/standards
MH  - Blotting, Western
MH  - Breast Neoplasms/blood/*genetics
MH  - Electrophoresis, Polyacrylamide Gel
MH  - Female
MH  - *Gene Amplification
MH  - Humans
MH  - Limit of Detection
MH  - Middle Aged
MH  - Receptor, ErbB-2/blood/*genetics/immunology
MH  - Reference Standards
MH  - Reproducibility of Results
EDAT- 2011/02/16 06:00
MHDA- 2011/07/21 06:00
CRDT- 2011/02/16 06:00
PHST- 2011/02/16 06:00 [entrez]
PHST- 2011/02/16 06:00 [pubmed]
PHST- 2011/07/21 06:00 [medline]
AID - 10.1515/CCLM.2011.135 [doi]
PST - ppublish
SO  - Clin Chem Lab Med. 2011 May;49(5):877-83. doi: 10.1515/CCLM.2011.135. Epub 2011 
      Feb 15.